Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions

Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions

Immune checkpoint inhibitor-based therapies represent the current standard of care in the first-line treatment of advanced renal cell carcinoma. Despite a clear benefit in survival outcomes, a considerable proportion of patients experience disease progression; prospective data about second-line ther...

Full description

Bibliographic Details
Main Authors: Enrico Sammarco, Fiorella Manfredi, Amedeo Nuzzo, Marco Ferrari, Adele Bonato, Alessia Salfi, Debora Serafin, Luca Zatteri, Andrea Antonuzzo, Luca Galli
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Cancers
Subjects:
renal cell carcinoma (RCC)
immune checkpoint inhibitors (ICIs)
rechallenge
resistance
combination treatment
Online Access:https://www.mdpi.com/2072-6694/15/12/3172

Internet

https://www.mdpi.com/2072-6694/15/12/3172

Similar Items